ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows.

(in thousands)	December 31, 2019		December 31, 2018
Cash and cash equivalents	$	91,028	$	43,695
Restricted cash, current	2,788		—
Restricted cash, noncurrent	—		4,973
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	93,816	$	48,668

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows.

(in thousands)	December 31, 2019		December 31, 2018
Cash and cash equivalents	$	91,028	$	43,695
Restricted cash, current	2,788		—
Restricted cash, noncurrent	—		4,973
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	93,816	$	48,668

Property and Equipment

Property and equipment consisted of the following:

(in thousands, except useful lives)	Estimated Useful Lives				December 31, 2019			December 31, 2018
Leasehold improvements			5	Years	$	3,944		$	21,633
Lab equipment			5	Years	5,459			8,471
Office furniture			5	Years	392			1,704
Manufacturing equipment			5	Years	395			1,890
Computer and office equipment	3	to	5	Years	1,595			1,606
Equipment held under capital leases			5	Years	270			204
Software			3	Years	385			361
Total					12,440			35,869
Less: accumulated depreciation					(9,911		)	(14,991		)
Property and equipment, net					$	2,529		$	20,878

Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consist of the following:

	December 31, 2019		December 31, 2018
Accrued payroll	$	2,032	$	3,430
Accrued patient treatment costs	1,162		2,053
Accrued manufacturing costs	2,230		546
Accrued professional services	654		235
Accrued obligations under material supply agreements	1,121		—
Accrued construction costs	—		457
Accrued other	2,571		1,868
Total accrued expenses and other current liabilities	$	9,770	$	8,589

Earnings Per Share, Potentially Dilutive Securities

The following outstanding shares of common stock equivalents were excluded from the computations of diluted net loss per shares of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive.

	December 31, 2019	December 31, 2018
Common stock equivalents:	Number of Shares
Redeemable convertible series 1 preferred stock	5,380,000	—
Warrants to purchase common stock	5,750,000	—
Options to purchase common stock	567,842	575,924
Unvested shares of restricted stock units	6,359	24,615
Total common stock equivalents	11,704,201	600,539